As a #DDW2024 presenter, I’ll help shape the future of digestive disease care. Join me at the premier meeting in GI as we pave the way for new advancements. Register now at app.ingo.me/q/040jh and see you there, May 18–21, 2024!

Have a look at our latest article on JCC🗞️! - IBD increases the risk of CKD - independent of therapy including 5-ASA - association less prominent with increasing age Screening for decreased renal function is therefore recommended. Bram Verstockt Björn Meijers  IBD Leuven ⬇️⬇️⬇️

why is it called a nanodrop if the drop measured is a microliter

I have to admit I love these 🧵 Super useful and a lot of info synthesized Thanks Laura for your fantastic effort 🤩

👩‍⚕️👨‍⚕️JAK inhibitors for IBD A 🔥 review ⤵️ ▪︎Summary of pivotal trial ▪︎Potential adverse events ▪︎checklist for initiating therapy

OCEAN study: The first randomized controlled study to compare octreotide treatment with standard of care in patients with angiodysplasia-related bleeding @Joostphdrenth Lia Lucas Bernts ow.ly/IPx050R8Nk8

New research - Chanchlani et al - Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn’s disease: 3-year data from the prospective, multicentre PANTS cohort study thelancet.com/journals/langa… #GITwitter #IBD

Delighted to see 🇬🇧 PANTS study 3 year extension data published in The Lancet Gastroenterology & Hepatology 🙏🏼 to the investigators and patients who participated sciencedirect.com/science/articl… ⏺️Only 1/3 of those treated with TNFis remain in remission at 3years ⏺️Week 14 levels significant in reducing

🥁Hi all, the Spring Issue of the ECCO News is out!!! Enjoy our articles and podcast! Here, you can find my article with an overview of ECCO 2024 Scientific and Educational Programmes. 👉🏻ecco-ibd.eu/publications/e…

Chronic kidney disease is more prevalent among patients with inflammatory bowel disease (IBD) vs healthy control individuals. Tommaso Innocenti Bram Verstockt Björn Meijers  #GItwitter #gastroenterology brnw.ch/21wJA9e

#WorldIBDDay

TDM in #IBD, when it refers at least to antiTNF there should be little to no debate on this topic at this stage but for some reason still is 🧐 Great summary from Adam Cheifetz At Digestive Disease Week #DDW2024

🟣 World IBD Day at #DDW2024 !! 🟣 #WorldIBDday

All united as a team, both in Washington #DDW2024 and in Leuven, for the benefit of our #IBD patients, day after day. Let’s move the needle all together. #Unitedwestand! Teamwork makes the dreamwork! #IBDLeuven WorldIBDday UZ Leuven KU Leuven TARGID KU LEUVEN

📢 #DDW2024 First in human study of a bio therapeutic agent MH002 in mild to moderate UC Severine Vermeire Promising results

Ileal Paneth Cell Phenotype is a Cellular Biomarker for #Pouch Complications in #UC Ma et al. academic.oup.com/ecco-jcc/advan…

🔥HOT OF THE PRESS🔥 Just published in CGH , in this Letter we demonstrated an optimal performance of the #IBUSSAS in #UC ! Gabriele Dragoni #CarmenRocco Many thanks to Rune Wilkens for commenting our work! Be ready to hear some IBUS-SAS data in UC at #UEGW2024 !! 🔭

🌟Can eLearning impact how you assess #intestinalultrasound images? In Journal of Crohn's and Colitis, we present a novel study on how deliberate practice can enhance your ability to score #IBD #inflammation (using) #IBUSSAS. Novices learned a lot over 80 cases. Experienced readers learned more about

The Impact of #PAD4-dependent Neutrophil Extracellular Trap #NAT Formation on the Early Development of Intestinal #Fibrosis in #CD Gabriele Dragoni Severine Vermeire Bo-Jun Ke @tommaso_innocenti Gianluca Matteoli Bram Verstockt andre dhoore Gabriele Bislenghi academic.oup.com/ecco-jcc/advan…

IL23R-specific CAR Tregs for the treatment of Crohn’s disease academic.oup.com/ecco-jcc/artic…